Fair Pay & Worker Respect

For the fiscal year ended December 31, 2024, the ratio of the CEO's annual total compensation to the median employee's annual total compensation was 20.9:1.

All employees, including Named Executive Officers, are eligible to participate in employee benefit plans such as medical, dental, and vision insurance on the same basis. The company reported having 203 full-time employees as of December 31, 2023, and none of these employees are represented by a labor union.

Kind to Animals

Vanda Pharmaceuticals has a strong public policy against unnecessary animal research, stating an ethical responsibility to reduce, refine, and replace animal experimentation to the maximum extent possible.

They have taken legal action against the FDA, filing a complaint in federal court, and published an open letter challenging the requirement for a nine-month dog toxicity study for their drug tradipitant. Vanda argues this study is unnecessary, unethical, and inhumane, and would result in the death of every canine participant. They advocate for limiting unnecessary animal testing and suggest that 9-month dog studies should be the exception. Vanda has collaborated with organizations like the Physicians Committee for Responsible Medicine and the Humane Society of the United States to urge Congress to task the FDA with moving away from dog studies and other animal testing. However, the company has conducted animal studies, including three-month rat, six-month rat, and three-month dog studies, and the FDA's requirement involves the death of dozens of dogs. There is no evidence of participation in multi-stakeholder initiatives to develop industry-wide animal-free testing and sourcing standards, nor any information on animal agriculture practices.

No War, No Weapons

Vanda Pharmaceuticals Inc. is a biopharmaceutical company.

Sustainalytics reports that the company has no involvement in Military Contracting, Controversial Weapons, or Small Arms. This indicates that the company has no revenue from arms or defense contracts, no exposure to controversial weapons, and no defense assets to divest, aligning with the 'N/A' tier for these KPIs as they are not applicable to its core business model.

Planet-Friendly Business

The provided articles indicate a significant lack of publicly available, specific, and quantitative data regarding Vanda Pharmaceuticals Inc.'s environmental performance. There is no information on carbon emissions, renewable energy use, water consumption, waste diversion, or any climate-related targets or initiatives.

The articles explicitly state data gaps concerning environmental, social, and governance (ESG) metrics and limited information on climate-related actions and targets.

Safe & Smart Tech

Vanda Pharmaceuticals conducts annual training for employees on customer data handling and use requirements, as well as cybersecurity management and incident response.

The company performs regular network and endpoint monitoring, vulnerability assessments, and penetration testing. Vanda also monitors emerging data protection laws and implements changes to ensure compliance. The company filed a lawsuit against the U.S. Food and Drug Administration (FDA) in May 2023, alleging the FDA improperly disclosed trade secrets to generic drug competitors, which Vanda claims violates trade secret laws and constitutes a Fifth Amendment takings claim. A court ruling on this matter occurred in January 2024, but the court has not yet determined the validity of Vanda's trade secret rights or if the alleged disclosure constitutes a taking.